MCID: PRC019
MIFTS: 47

Precocious Puberty

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Precocious Puberty

MalaCards integrated aliases for Precocious Puberty:

Name: Precocious Puberty 52 36 29 71 32
Cryptogenic Sexual Precocity 71
Familial Precocious Puberty 52
Idiopathic Sexual Precocity 52
Puberty Precocious 54
Sexual Precocity 52

Classifications:



External Ids:

KEGG 36 H00937
ICD10 32 E30.1
UMLS 71 C0034013 C0271527

Summaries for Precocious Puberty

KEGG : 36 Precocious puberty has been classically defined as the onset of secondary sexual characteristics in girls younger than 8 years old and in boys younger than 9 and a half years old. Central precocious puberty (CEPREPU) refers to a gonadotropin-dependent type which results from premature activation of the hypothalamic-pituitary-gonadal axis (HPG). CEPREPU is much more frequent in girls than in boys (up to 20:1 ratio). Recently, kisspeptin receptor (KISS1R) and its ligand, kisspeptin, were revealed as major gatekeepers of puberty onset. Mutations of the KISS1R gene were described in patients with impaired pubertal development. On the other hand, it has been reported that heterozygous mutations of the LHCGR gene cause gonadotropin-independent precocious puberty in males, but have no detectable effects on prepubertal or postpubertal females.

MalaCards based summary : Precocious Puberty, also known as cryptogenic sexual precocity, is related to precocious puberty, male-limited and idiopathic central precocious puberty. An important gene associated with Precocious Puberty is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are Calcium signaling pathway and Neuroactive ligand-receptor interaction. The drugs Megestrol acetate and Leuprolide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and brain, and related phenotypes are adipose tissue and endocrine/exocrine gland

NIH Rare Diseases : 52 Precocious puberty is when a person's sexual and physical traits develop and mature earlier than normal. Normal puberty typically begins between ages 10 and 14 for girls, and ages 12 and 16 for boys. The start of puberty depends on various factors such as family history , nutrition and gender. The cause of precocious puberty is not always known. Some cases of precocious puberty are due to conditions that cause changes in the body's release of hormones . Treatment involves medications that can stop the release of sexual hormones.

Wikipedia : 74 In medicine, precocious puberty is puberty occurring at an unusually early age. In most cases, the... more...

Related Diseases for Precocious Puberty

Diseases in the Precocious Puberty family:

Precocious Puberty, Central, 1 Precocious Puberty, Central, 2
Central Precocious Puberty Secondary Central Precocious Puberty
Rare Precocious Puberty

Diseases related to Precocious Puberty via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 precocious puberty, male-limited 34.5 LHCGR CYP19A1
2 idiopathic central precocious puberty 33.7 MKRN3 KISS1R KISS1
3 central precocious puberty 33.2 MKRN3 KISS1R KISS1 GNRH1 GH1
4 aromatase excess syndrome 32.8 GNRH1 CYP19A1
5 mccune-albright syndrome 32.8 GNAS GH1 CYP19A1
6 hypothalamic hamartomas 32.4 KISS1R KISS1 GNRH1
7 fibrous dysplasia 31.1 GNAS GH1
8 hypogonadotropism 30.7 KISS1R KISS1 GNRH1
9 hyperprolactinemia 30.5 GNRH1 GNAS GH1
10 ovarian cyst 30.5 GNRH1 GNAS CYP19A1
11 empty sella syndrome 30.5 GNRH1 GH1
12 hypothalamic disease 30.4 GNRH1 GH1
13 fibrous dysplasia/mccune-albright syndrome 30.4 GNAS GH1
14 lipoid congenital adrenal hyperplasia 30.4 GNRH1 CYP21A2 CYP19A1
15 prader-willi syndrome 30.3 MKRN3 GNRH1 GH1
16 pituitary tumors 30.3 GNAS GH1
17 estrogen excess 30.2 GNRH1 CYP19A1
18 adrenal adenoma 30.1 GNAS CYP21A2
19 vaginal discharge 30.0 GNRH1 CYP19A1
20 pituitary adenoma 30.0 GNRH1 GNAS GH1
21 gynecomastia 30.0 GNRH1 CYP21A2 CYP19A1
22 pseudohypoparathyroidism, type ia 29.9 GNAS GH1
23 pituitary gland disease 29.9 GNRH1 GNAS GH1
24 hypothyroidism 29.9 GNRH1 GNAS GH1
25 functioning pituitary adenoma 29.9 GNAS GH1
26 adenoma 29.9 LHCGR GNAS GH1 CYP21A2
27 infertility 29.9 LHCGR GNRH1 CYP19A1
28 amenorrhea 29.8 LHCGR GNRH1 CYP19A1
29 sex cord-gonadal stromal tumor 29.8 GNAS CYP19A1
30 acanthosis nigricans 29.8 GH1 CYP21A2
31 premature menopause 29.7 GNRH1 CYP19A1
32 normosmic congenital hypogonadotropic hypogonadism 29.6 KISS1R KISS1 GNRH1
33 polycystic ovary syndrome 29.6 GNRH1 GH1 CYP21A2 CYP19A1
34 pituitary adenoma, prolactin-secreting 29.6 GNRH1 GNAS GH1
35 acromegaly 29.6 GNRH1 GNAS GH1
36 hyperandrogenism 29.5 GNRH1 GH1 CYP21A2 CYP19A1
37 hypogonadotropic hypogonadism 29.3 LHCGR KISS1R KISS1 GNRH1 CYP19A1
38 luteoma 29.3 GNRH1 CYP21A2 CYP19A1
39 leydig cell tumor 29.2 LHCGR GNRH1 GNAS CYP21A2 CYP19A1
40 kallmann syndrome 29.2 MKRN3 KISS1R KISS1 GNRH1
41 conn's syndrome 28.9 LHCGR GNRH1 GNAS GH1 CYP21A2
42 cryptorchidism, unilateral or bilateral 28.9 LHCGR KISS1R KISS1 GNRH1 CYP19A1
43 hypogonadism 28.8 LHCGR KISS1R KISS1 GNRH1 GH1 CYP19A1
44 body mass index quantitative trait locus 11 28.8 GNAS GH1 CYP21A2 CYP19A1
45 anovulation 28.7 KISS1 GNRH1 CYP21A2 CYP19A1
46 premature ovarian failure 1 28.5 LHCGR KISS1R KISS1 GNRH1 CYP19A1
47 precocious puberty, central, 2 12.9
48 familial male-limited precocious puberty 12.9
49 precocious puberty, central, 1 12.9
50 spastic paraplegia with precocious puberty 12.7

Graphical network of the top 20 diseases related to Precocious Puberty:



Diseases related to Precocious Puberty

Symptoms & Phenotypes for Precocious Puberty

MGI Mouse Phenotypes related to Precocious Puberty:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.77 CYP19A1 GNAS KISS1 KISS1R LHCGR
2 endocrine/exocrine gland MP:0005379 9.73 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR
3 digestive/alimentary MP:0005381 9.72 CYP19A1 GNRH1 KISS1 KISS1R LHCGR
4 integument MP:0010771 9.63 CYP19A1 CYP21A2 GNAS GNRH1 KISS1 KISS1R
5 liver/biliary system MP:0005370 9.43 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR
6 renal/urinary system MP:0005367 9.1 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR

Drugs & Therapeutics for Precocious Puberty

Drugs for Precocious Puberty (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
2
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
3
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
4
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
5 Luteolytic Agents Phase 4
6 Triptorelin Pamoate Phase 4
7 Fertility Agents Phase 4
8 Hormone Antagonists Phase 4
9 Hormones Phase 4
10 Central Nervous System Stimulants Phase 4
11
Megestrol Phase 4 3562-63-8 3080587 19090
12 Appetite Stimulants Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 Contraceptive Agents Phase 4
15 Contraceptives, Oral Phase 4
16 Progestins Phase 4
17
Medroxyprogesterone Phase 4 520-85-4 10631
18 Contraceptive Agents, Male Phase 4
19 Pharmaceutical Solutions Phase 3
20
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
21
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
22
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 6013 10204
23
Metformin Approved Phase 2 657-24-9 4091 14219
24
Spironolactone Approved Phase 2 52-01-7, 1952-01-7 5833
25
Testolactone Approved, Investigational Phase 2 968-93-4 13769
26
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
27
Racepinephrine Approved Phase 2 329-65-7 838
28
Alendronate Approved Phase 2 66376-36-1, 121268-17-5 2088
29
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
30
Zinc Approved, Investigational Phase 2 7440-66-6 32051
31
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
32
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
33
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
34 Steroid Synthesis Inhibitors Phase 2
35 Androgen Antagonists Phase 2
36 Aromatase Inhibitors Phase 2
37 Prolactin Release-Inhibiting Factors Phase 2
38 Hypoglycemic Agents Phase 2
39 Mineralocorticoid Receptor Antagonists Phase 2
40 Mineralocorticoids Phase 2
41 Natriuretic Agents Phase 2
42 Diuretics, Potassium Sparing Phase 2
43 diuretics Phase 2
44 Epinephryl borate Phase 2
45 Adrenergic Agonists Phase 2
46 Adrenergic beta-Agonists Phase 2
47 Respiratory System Agents Phase 2
48 Neurotransmitter Agents Phase 2
49 Sympathomimetics Phase 2
50 Bronchodilator Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
2 A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Unknown status NCT03316482 Phase 4 Leuplin DPS 11.25mg
3 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
4 Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls. Unknown status NCT01278290 Phase 4 Triptorelin acetate and Gonadorelin acetate;Gonadorelin acetate and Triptorelin acetate
5 The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
6 Multi-site Study of Comprehensive Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
7 An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty Completed NCT02427958 Phase 4 Leuprorelin
8 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
9 Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Not yet recruiting NCT03963752 Phase 4 Ziyinxiehuo granules Herbs;Megestrol Acetate Tablet;Leuprorelin Acetate 3.75mg Injection
10 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
11 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
12 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
13 An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty Completed NCT01467882 Phase 3 Triptorelin
14 Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty Completed NCT00909844 Phase 3 Triptorelin (I.N.N.)
15 An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty Completed NCT02452931 Phase 3 Leuprolide Acetate 45 mg
16 A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty Completed NCT00635817 Phase 3 Leuprolide acetate 11.25 mg;Leuprolide acetate 30 mg
17 Phase III, Multicentre, Non-comparative, Open and Single Stage Study to Assess the Efficacy and Safety of Pamoate of Triptorelin 11.25 MG in Children With Precocious Puberty Completed NCT00564850 Phase 3 Triptorelin pamoate 11.25mg (Decapeptyl® SR)
18 Study of Lupron Depot In The Treatment of Central Precocious Puberty Completed NCT00660010 Phase 3 Lupron (leuprolide acetate)
19 A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty Completed NCT00667446 Phase 3 Leuprolide Acetate 3 Month Depot
20 Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty Completed NCT00779103 Phase 3 Histrelin Subcutaneous Implant
21 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
22 A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP) Recruiting NCT03695237 Phase 3 Leuprolide Acetate (LA)
23 An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis Completed NCT00094328 Phase 2 Bicalutamide;Anastrozole
24 Spironolactone and Testolactone Treatment of Boys With Familial Isosexual Precocious Puberty Completed NCT00001202 Phase 2 Spironolactone;Testolactone;Deslorelin
25 Testolactone Treatment of Girls With LHRH Analog-Resistant Precocious Puberty Due to Autonomous, Non-Neoplastic Ovarian Estrogen Secretion Completed NCT00001181 Phase 2 Testolactone
26 An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome Completed NCT00055302 Phase 2 Arimidex 1 mg
27 A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature Completed NCT00001190 Phase 2 Deslorelin
28 3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients With Uterine Fibroids Completed NCT00776074 Phase 2 Leuprorelin (GF);Leuprorelin (GC)
29 A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome Completed NCT00001728 Phase 2 Fosamax (Alendronate)
30 EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrome W) Completed NCT00618072 Phase 2 metformin and rosiglitazone
31 A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2 Hydrocortisone (Solucortef)
32 An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome Active, not recruiting NCT00278915 Phase 2 Fulvestrant
33 A Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants After Cardiac Surgery Unknown status NCT01048632 Phase 1 Oxandrolone
34 Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS) Completed NCT00006174 Phase 1 Letrozole
35 Urinary LH in the Diagnosis of Precocious Puberty Unknown status NCT01800565
36 LH Response to GnRH Test in Prepubescent Girls Under 6 Years Unknown status NCT01944488 GnRH agonist
37 Influence of Early Adiposity Rebound, Genetic Polymorphisms and GnRHa Treatment on Long-term Outcome of Girls With Idiopathic Central Precocious Puberty. Unknown status NCT02790112
38 Follow-up of Girls With Premature Thelarche and Precocious Puberty: a Clinical and Paraclinical Study of Girls With Thelarche and Healthy Controls Unknown status NCT01944475
39 Cohort Study to Investigate the Relationship Between Ultrasound Apparatus Results (SonicBone's BAUS) and Skeletal Maturity Status (Bone Age) Among Healthy Children and Adolescence Unknown status NCT01980693
40 A Comparison of Bone Age Assessment by an Ultrasound Apparatus (SonicBone) and the X-ray Based Grulich and Pyle Method Unknown status NCT01346618
41 Effects of Single Nucleotide Polymorphism of GnRH Receptor Genes on Clinical Response to Pituitary Down Regulation in IVF Patients Unknown status NCT02979886 GnRH-a;Human Menopausal Gonadotropins
42 Purification of Testis-Stimulating Factor in Precocious Puberty Completed NCT00004344 leuprolide;testosterone
43 Efficacy of Experienced Chinese Herbal Formulas for the Treatment of Different Types of Precocious Puberty: A Single-blinded Randomized Controlled Trial Completed NCT02650141 ziyinxiehuo Granules;zishenqinggan Granules
44 Qualitative Assessment of the Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years Completed NCT01679925
45 Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Precocious Puberty Completed NCT02431416 Gonadotropin releasing hormone (GnRH);Sodium Chloride
46 Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle Completed NCT00004335
47 An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty Completed NCT02993926 Enantone;GnRH agonist
48 Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Completed NCT00734279 Early Phase 1 Leuprolide Acetate - Early Puberty Leuprolide Visit;Ganirelix - Early Puberty Ganirelix Visit;Ganirelix - Delayed Puberty Ganirelix Visit;Leuprolide Acetate- Delayed Puberty Leuprolide Visit
49 The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or Growth Hormone Provocation Test Completed NCT02199587
50 Polymorphisms in the Kisspeptin/GPR54 Pathway Genes and the Risk of Early Puberty Completed NCT04012632

Search NIH Clinical Center for Precocious Puberty

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Gonadorelin
Gonadorelin Acetate
Gonadorelin Hydrochloride
Leuprolide
Leuprolide Acetate
Nafarelin
Nafarelin Acetate
Tamoxifen
Tamoxifen Citrate

Genetic Tests for Precocious Puberty

Genetic tests related to Precocious Puberty:

# Genetic test Affiliating Genes
1 Precocious Puberty 29

Anatomical Context for Precocious Puberty

MalaCards organs/tissues related to Precocious Puberty:

40
Pituitary, Bone, Brain, Ovary, Testes, Pineal, Testis

Publications for Precocious Puberty

Articles related to Precocious Puberty:

(show top 50) (show all 4051)
# Title Authors PMID Year
1
Central precocious puberty due to hypothalamic hamartomas correlates with anatomic features but not with expression of GnRH, TGFalpha, or KISS1. 54 61
20389100 2010
2
Thyroid autoimmunity and miscarriages: the corpus luteum hypothesis. 54 61
19505771 2009
3
No activating mutations of FSH receptor in four children with ovarian juvenile granulosa cell tumors and the association of these tumors with central precocious puberty. 54 61
19539204 2009
4
Subcutaneous gonadotropin-releasing hormone agonist (triptorelin) test for diagnosing precocious puberty. 61 54
19690429 2009
5
Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. 54 61
19176945 2009
6
A case of X-linked adrenal hypoplasia congenita, central precocious puberty and absence of the DAX-1 gene: implications for pubertal regulation. 54 61
19339795 2009
7
ACTH-dependent precocious pseudopuberty in an infant with DAX1 gene mutation. 54 61
18414894 2009
8
[Advances on related genes with sexual precocity in mammals]. 61 54
19138897 2009
9
Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty. 61 54
19209621 2008
10
[Relationship of plasma ghrelin and adenohypophyseal hormone levels in female precocious puberty]. 54 61
18925720 2008
11
A 46XX disorder of sex development with a prostate gland and increased level of prostate-specific antigen. 61 54
18300543 2008
12
Diversity of actions of GnRHs mediated by ligand-induced selective signaling. 61 54
17976709 2008
13
Predictive factors for organic central precocious puberty and utility of simplified gonadotropin-releasing hormone tests. 54 61
18045276 2007
14
Leuprolide acetate: a drug of diverse clinical applications. 61 54
17970643 2007
15
Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? 61 54
18183790 2007
16
Early maturation of gonadotropin-releasing hormone secretion and sexual precocity after exposure of infant female rats to estradiol or dichlorodiphenyltrichloroethane. 61 54
17596564 2007
17
Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment. 61 54
17519314 2007
18
Association study of the polymorphisms in the KISS1 gene with central precocious puberty in Chinese girls. 61 54
17609410 2007
19
Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. 61 54
17684302 2007
20
Regulation of circulating leptin and its soluble receptor during pubertal development in the male rhesus monkey (Macaca mulatta). 54 61
17873322 2007
21
Insights learned from L457(3.43)R, an activating mutant of the human lutropin receptor. 61 54
17055147 2007
22
Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. 61 54
17125443 2006
23
Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune-Albright syndrome. 54 61
17101633 2006
24
A constitutively active mutant of the human lutropin receptor (hLHR-L457R) escapes lysosomal targeting and degradation. 61 54
16803865 2006
25
A single somatic activating Asp578His mutation of the luteinizing hormone receptor causes Leydig cell tumour in boys with gonadotropin-independent precocious puberty. 54 61
16918965 2006
26
Variable presentation of precocious puberty associated with the D564G mutation of the LHCGR gene in children with testotoxicosis. 54 61
16887451 2006
27
Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. 54 61
16757104 2006
28
Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. 54 61
16787697 2006
29
Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. 54 61
16728550 2006
30
McCune-Albright syndrome: growth hormone and prolactin hypersecretion. 54 61
16789626 2006
31
Congenital adrenal hyperplasia in the Bahamas due to 21-hydroxylase deficiency. 54 61
16921705 2006
32
Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty. 54 61
17002488 2006
33
The histrelin implant: a novel treatment for central precocious puberty. 61 54
16322137 2005
34
Control of puberty by excitatory amino acid neurotransmitters and its clinical implications. 54 61
16388117 2005
35
The gonadotrophins response to GnRH test is not a predictor of neurological lesion in girls with central precocious puberty. 61 54
16279361 2005
36
New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. 54 61
16144493 2005
37
Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children. 61 54
16169408 2005
38
Leptin changes in Taiwanese girls with central precocious puberty before and during the GnRH agonist treatment. 61 54
16640001 2005
39
Gonadotropin-releasing hormone analogue treatment for precocious puberty. Twenty years of experience. 61 54
15722620 2005
40
Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. 61 54
15995342 2005
41
Non-peptidic GnRH receptor antagonists. 54 61
15544487 2004
42
[Simplified gonadorelin stimulation test in diagnosis of precocious puberty]. 54 61
15476332 2004
43
Activating GNAS1 gene mutations in patients with premature thelarche. 54 61
15289771 2004
44
[Clinical application of simplified gonadotropin releasing hormone stimulating test in management of female isosexual precocious puberty]. 61 54
15312320 2004
45
Aromatase inhibitors in precocious puberty: rationale and experience to date. 54 61
16026110 2004
46
Clinical and molecular analysis of human reproductive disorders in Brazilian patients. 54 61
14689055 2004
47
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. 54 61
14671160 2003
48
Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature. 61 54
13680381 2003
49
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 in girls with premature thelarche. 61 54
12948294 2003
50
Final adult height in "early normal pubertal girls" treated with gonadotropin releasing hormone agonists. 54 61
12929985 2003

Variations for Precocious Puberty

Expression for Precocious Puberty

Search GEO for disease gene expression data for Precocious Puberty.

Pathways for Precocious Puberty

Pathways related to Precocious Puberty according to KEGG:

36
# Name Kegg Source Accession
1 Calcium signaling pathway hsa04020
2 Neuroactive ligand-receptor interaction hsa04080
3 GnRH signaling pathway hsa04912

GO Terms for Precocious Puberty

Biological processes related to Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cognition GO:0050890 9.26 LHCGR GNAS
2 activation of adenylate cyclase activity GO:0007190 9.16 LHCGR GNAS
3 G protein-coupled receptor signaling pathway GO:0007186 9.02 LHCGR KISS1R KISS1 GNRH1 GNAS
4 sterol metabolic process GO:0016125 8.96 CYP21A2 CYP19A1

Molecular functions related to Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled peptide receptor activity GO:0008528 8.96 LHCGR KISS1R
2 steroid hydroxylase activity GO:0008395 8.62 CYP21A2 CYP19A1

Sources for Precocious Puberty

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....